Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005480 | 0.98 | KEAP1 (0.57) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL1239113 | 0.98 | KEAP1 (0.57) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL30851436 | 0.98 | KEAP1 (0.57) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL27412576 | 0.96 | KEAP1 (0.55) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL23161511 | 0.95 | SMN1; SMN2 (0.56) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL29709408 | 0.87 | ALDH1A1 (0.54) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL4717743 | 0.82 | NCF1 (0.59) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL19187683 | 0.82 | ADRB1 (0.55) | ALDH1A1TSHRKDM4EHSD17B10CYP1A2 | |
| SCHEMBL1267622 | 0.82 | SMN1; SMN2 (0.53) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB | |
| SCHEMBL5716237 | 0.82 | DRD2 (0.47) | ALDH1A1TSHRSMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0211805-A2 | N-(2-fluorophenyl)azolidines | CIBA-GEIGY AG (CH) | 1987-02-25 | — | — | EP | claimed |
| CN-117126093-B | Preparation method of voronoi intermediate | 潍坊医学院 | 2023-12-29 | — | — | CN | disclosed |
| CN-117126093-A | Preparation method of voronoi intermediate | 潍坊医学院 | 2023-11-28 | — | — | CN | disclosed |
| EP-3788042-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2021-03-10 | — | — | EP | disclosed |
| US-9624238-B2 | 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-09-11 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-1707202-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| EP-0364797-B1 | N-aryl-nitrogenated heterocycles, process for their preparation and their use as herbicides | BAYER AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| EP-0211805-A3 | N-(2-FLUOROPHENYL)AZOLIDINES | CIBA-GEIGY AG (CH) | 1988-01-13 | — | — | EP | disclosed |
| EP-0211805-A3 | N-(2-FLUOROPHENYL)AZOLIDINES | CIBA-GEIGY AG (CH) | 1988-01-13 | — | — | EP | disclosed |
| EP-0211805-A2 | N-(2-fluorophenyl)azolidines | CIBA-GEIGY AG (CH) | 1987-02-25 | — | — | EP | disclosed |
| EP-0211805-A2 | N-(2-fluorophenyl)azolidines | CIBA-GEIGY AG (CH) | 1987-02-25 | — | — | EP | disclosed |
| EP-0211805-A2 | N-(2-fluorophenyl)azolidines | CIBA-GEIGY AG (CH) | 1987-02-25 | — | — | EP | disclosed |
| US-4500715-A | CHEMICAL INTERMEDIATES FOR PLANT SAFENING AGENTS AND DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-02-19 | — | — | US | disclosed |
| US-4268438-A | Cationic 1,3,4-thiadiazole dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, CES1, ACHE | ALDH1A1 1022/4885TSHR 3034/4885SMN1; SMN2 3963/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | ALDH1A1 1248/4885TSHR 4626/4885SMN1; SMN2 2196/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | ALDH1A1 1248/4885TSHR 4626/4885SMN1; SMN2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.